HK1250142A1 - 以組織蛋白去乙醯酶抑制劑及反細胞程式死亡受體-1 抗體的組合治療癌症 - Google Patents
以組織蛋白去乙醯酶抑制劑及反細胞程式死亡受體-1 抗體的組合治療癌症Info
- Publication number
- HK1250142A1 HK1250142A1 HK18109582.5A HK18109582A HK1250142A1 HK 1250142 A1 HK1250142 A1 HK 1250142A1 HK 18109582 A HK18109582 A HK 18109582A HK 1250142 A1 HK1250142 A1 HK 1250142A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- antibody
- cancer
- treatment
- combination
- hdac inhibitor
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
- 229940121372 histone deacetylase inhibitor Drugs 0.000 title 1
- 239000003276 histone deacetylase inhibitor Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Mycology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Oncology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562136303P | 2015-03-20 | 2015-03-20 | |
US201562137601P | 2015-03-24 | 2015-03-24 | |
PCT/US2016/023298 WO2016154068A1 (en) | 2015-03-20 | 2016-03-18 | Combination of hdac inhibitor and anti-pd-1 antibody for treatment of cancer |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1250142A1 true HK1250142A1 (zh) | 2018-11-30 |
Family
ID=56977796
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK18109582.5A HK1250142A1 (zh) | 2015-03-20 | 2018-07-24 | 以組織蛋白去乙醯酶抑制劑及反細胞程式死亡受體-1 抗體的組合治療癌症 |
Country Status (12)
Country | Link |
---|---|
US (2) | US11324822B2 (zh) |
EP (1) | EP3270966B1 (zh) |
JP (2) | JP2018508593A (zh) |
KR (1) | KR20170124604A (zh) |
CN (1) | CN107614011A (zh) |
AU (2) | AU2016235434B2 (zh) |
BR (1) | BR112017020002A2 (zh) |
CA (1) | CA2980297A1 (zh) |
HK (1) | HK1250142A1 (zh) |
IL (2) | IL254529B2 (zh) |
MX (1) | MX2017012113A (zh) |
WO (1) | WO2016154068A1 (zh) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10478494B2 (en) | 2015-04-03 | 2019-11-19 | Astex Therapeutics Ltd | FGFR/PD-1 combination therapy for the treatment of cancer |
EP3345002A4 (en) | 2015-09-02 | 2019-05-08 | Syndax Pharmaceuticals Inc. | SELECTION OF PATIENTS FOR POLYTHERAPY |
EP3400009A2 (en) * | 2016-01-05 | 2018-11-14 | The U.S.A. As Represented By The Secretary, Department Of Health And Human Services | Combination of histone deacetylase inhibitor and immunotherapy |
EP3407913A1 (en) * | 2016-01-28 | 2018-12-05 | Indiana University Research & Technology Corporation | Use of histone deacetylase inhibitors for enhancing immunotherapies |
TWI794171B (zh) | 2016-05-11 | 2023-03-01 | 美商滬亞生物國際有限公司 | Hdac抑制劑與pd-l1抑制劑之組合治療 |
TWI808055B (zh) | 2016-05-11 | 2023-07-11 | 美商滬亞生物國際有限公司 | Hdac 抑制劑與 pd-1 抑制劑之組合治療 |
WO2018098168A1 (en) * | 2016-11-23 | 2018-05-31 | Acetylon Pharmaceuticals, Inc. | Pharmaceutical combinations comprising a histone deacetylase inhibitor and a programmed death-ligand 1 (pd-l1) inhibitor and methods of use thereof |
MA50070A (fr) * | 2017-09-08 | 2020-07-15 | 4Sc Ag | Inhibiteur de l'histone désacétylase en association avec un modulateur de point de contrôle immunitaire pour la cancérothérapie |
US20210024633A1 (en) * | 2018-03-28 | 2021-01-28 | Ensemble Group Holdings | Methods of treating cancer in subjects having dysregulated lymphatic systems |
US20190380998A1 (en) * | 2018-06-15 | 2019-12-19 | The Board Of Regents Of The University Of Texas System | Methods of treating and preventing melanoma with s-equol |
KR20210028339A (ko) * | 2019-09-04 | 2021-03-12 | 크리스탈지노믹스(주) | Hdac 저해제와 항 pd-1 항체 또는 항 pd-l1 항체를 포함하는 약학 조성물 |
TW202128224A (zh) * | 2019-12-23 | 2021-08-01 | 大陸商信達生物製藥(蘇州)有限公司 | 抗pd-1抗體和組蛋白去乙醯化酶抑制劑的藥物組合及其用途、使用方法 |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4328245A (en) | 1981-02-13 | 1982-05-04 | Syntex (U.S.A.) Inc. | Carbonate diester solutions of PGE-type compounds |
US4410545A (en) | 1981-02-13 | 1983-10-18 | Syntex (U.S.A.) Inc. | Carbonate diester solutions of PGE-type compounds |
US4409239A (en) | 1982-01-21 | 1983-10-11 | Syntex (U.S.A.) Inc. | Propylene glycol diester solutions of PGE-type compounds |
US6350458B1 (en) | 1998-02-10 | 2002-02-26 | Generex Pharmaceuticals Incorporated | Mixed micellar drug deliver system and method of preparation |
US20130150386A1 (en) | 2011-12-09 | 2013-06-13 | Syndax Pharmaceuticals, Inc. | Methods for the treatment of lung cancer |
US8987067B2 (en) * | 2013-03-01 | 2015-03-24 | International Business Machines Corporation | Segmented guard ring structures with electrically insulated gap structures and design structures thereof |
EP3027210A1 (en) * | 2013-08-02 | 2016-06-08 | Aduro Biotech Holdings, Europe B.V. | Combining cd27 agonists and immune checkpoint inhibition for immune stimulation |
US10966998B2 (en) | 2013-09-05 | 2021-04-06 | The Johns Hopkins University | Cancer therapy via a combination of epigenetic modulation and immune modulation |
US9987258B2 (en) * | 2014-04-06 | 2018-06-05 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Histone deacetylase as a modulator of PDL1 expression and activity |
US10869926B2 (en) * | 2014-07-15 | 2020-12-22 | The Johns Hopkins University | Suppression of myeloid derived suppressor cells and immune checkpoint blockade |
TWI716362B (zh) * | 2014-10-14 | 2021-01-21 | 瑞士商諾華公司 | 針對pd-l1之抗體分子及其用途 |
WO2017004092A1 (en) * | 2015-06-29 | 2017-01-05 | Syndax Pharmaceuticals, Inc. | Combination of hdac inhibitor and anti-pd-l1 antibody for treatment of cancer |
EP3345002A4 (en) * | 2015-09-02 | 2019-05-08 | Syndax Pharmaceuticals Inc. | SELECTION OF PATIENTS FOR POLYTHERAPY |
-
2016
- 2016-03-18 BR BR112017020002A patent/BR112017020002A2/pt active Search and Examination
- 2016-03-18 CA CA2980297A patent/CA2980297A1/en active Pending
- 2016-03-18 AU AU2016235434A patent/AU2016235434B2/en active Active
- 2016-03-18 JP JP2018500281A patent/JP2018508593A/ja active Pending
- 2016-03-18 IL IL254529A patent/IL254529B2/en unknown
- 2016-03-18 EP EP16769460.3A patent/EP3270966B1/en active Active
- 2016-03-18 MX MX2017012113A patent/MX2017012113A/es unknown
- 2016-03-18 CN CN201680028952.1A patent/CN107614011A/zh active Pending
- 2016-03-18 KR KR1020177030064A patent/KR20170124604A/ko not_active IP Right Cessation
- 2016-03-18 WO PCT/US2016/023298 patent/WO2016154068A1/en active Application Filing
- 2016-03-18 US US15/559,402 patent/US11324822B2/en active Active
- 2016-03-18 IL IL307850A patent/IL307850A/en unknown
-
2018
- 2018-07-24 HK HK18109582.5A patent/HK1250142A1/zh unknown
-
2021
- 2021-08-10 JP JP2021130582A patent/JP2021175754A/ja active Pending
-
2022
- 2022-04-08 US US17/716,547 patent/US20230022573A1/en active Pending
- 2022-05-03 AU AU2022202954A patent/AU2022202954A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
IL307850A (en) | 2023-12-01 |
CA2980297A1 (en) | 2016-09-29 |
CN107614011A (zh) | 2018-01-19 |
AU2016235434A1 (en) | 2017-10-12 |
EP3270966B1 (en) | 2024-05-01 |
MX2017012113A (es) | 2018-07-06 |
IL254529B2 (en) | 2024-05-01 |
WO2016154068A1 (en) | 2016-09-29 |
AU2022202954A1 (en) | 2022-05-26 |
EP3270966A4 (en) | 2018-10-17 |
US20230022573A1 (en) | 2023-01-26 |
US11324822B2 (en) | 2022-05-10 |
US20180078639A1 (en) | 2018-03-22 |
BR112017020002A2 (pt) | 2018-06-19 |
IL254529A0 (en) | 2017-11-30 |
KR20170124604A (ko) | 2017-11-10 |
EP3270966A1 (en) | 2018-01-24 |
AU2016235434B2 (en) | 2022-02-03 |
JP2021175754A (ja) | 2021-11-04 |
RU2017134315A3 (zh) | 2019-09-12 |
IL254529B1 (en) | 2024-01-01 |
JP2018508593A (ja) | 2018-03-29 |
RU2017134315A (ru) | 2019-04-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1250142A1 (zh) | 以組織蛋白去乙醯酶抑制劑及反細胞程式死亡受體-1 抗體的組合治療癌症 | |
HK1255916A1 (zh) | 組織蛋白去乙醯酶抑制劑與免疫檢查點抑制抗體的合併癌症治療 | |
IL282962A (en) | Anti-PD-1 antibodies and methods of using them | |
HK1250513A1 (zh) | 抗ox40抗體及其使用方法 | |
IL258955A (en) | Preparations and methods for the treatment of cancer | |
DK3458478T3 (da) | Anti-pd-1- og anti-lag3-antistoffer til cancerbehandling | |
IL267804A (en) | Methods for treating cancer with anti-pd-1 antibodies | |
IL262562A (en) | Combination of anti-pd-1 antibodies and radiation for cancer therapy | |
IL265541B1 (en) | Bispecific antibodies and compounds containing them for the treatment of cancer | |
EP3383914A4 (en) | ANTI-OX40 ANTIBODIES AND METHODS OF USE | |
IL254131A0 (en) | Fidi-1 / Fidi-AL1 inhibitors for cancer treatment | |
IL259713A (en) | Anti-dr5 antibodies and methods of using them | |
IL289766A (en) | tfpi inhibitory antibodies and their uses | |
DK3178849T3 (da) | Kombination af anti-lag-3-antistoffer og anti-pd-1-antistoffer til behandling af tumorer | |
IL259416A (en) | Combination of hdac inhibitor and anti-pd-l1 antibody for treatment of ovarian cancer | |
IL269718A (en) | Combination of anti-PD-L1 antibody and DNA-PK inhibitor for cancer treatment | |
EP3370773A4 (en) | POLYTHERAPY COMPRISING IMMUNOTOXINS AND A CONTROL POINT INHIBITOR | |
IL274198A (en) | Use of Nox inhibitors to treat cancer | |
EP3727374A4 (en) | COMBINATION OF AN ANTI-PD-L1 ANTIBODY AND AN IDO1 INHIBITOR FOR THE TREATMENT OF CANCER | |
EP3126520A4 (en) | Biomarkers and use of met inhibitor for treatment of cancer | |
GB201418640D0 (en) | Agents and methods for treatment of cancer |